Previous 10 | Next 10 |
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...
GW Pharmaceuticals PLC (GWPH) 40th Annual Goldman Sachs Global Healthcare Conference Call June 11, 2019 2:20 PM ET Company Participants Stephen Schultz - Vice President of Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs & Co. Presentation ...
CannabisNewsWire Editorial Coverage : Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) ( LXRP Profile ) has recently seen spectacular improvements in the effectiveness of cannabino...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
The US Food and Drug Administration (FDA) held a public hearing last week to obtain scientific data about the safety, manufacturing, product quality, labeling, marketing, and sale of products containing cannabis or cannabis-derived compounds. However, despite lasting 10 hours an...
Stacking Up Cannabis Stocks To The Bluechips This week, we compare many corporate fundamentals of the ‘Cannabis 50’ companies to the largest 50 of the S&P 500 companies. Investor euphoria over the past several years has been concentrated in the Monsters of Tech (Apple (AA...
CARLSBAD, Calif., June 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announ...
Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...
CannabisNewsWire Editorial Coverage : Fueled by an explosion of CBD-infused edibles, billion-dollar projections for the CBD market may even be conservative. This seems possible when one considers the truly innovative work being done in the sector by the likes of Lexaria Bioscience Corp. (C...
News, Short Squeeze, Breakout and More Instantly...
GW Pharmaceuticals Plc Company Name:
GWPH Stock Symbol:
NASDAQ Market:
GW Pharmaceuticals Plc Website:
The key to investing is “Buy low, sell high”. According to that mantra, periods of weakness are the mother’s milk of future gains. When you see them, you know “this is my chance”. It’s the chance to get involved. This is especially true in industries ...
NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...
Real Brands Inc (OTCMKTS:RLBD) snuck one under the radar late last week, but investors interested in the CBD and Cannabis space should take note. The company filed its Form 10 with the SEC. In this case, it was a voluntary filing because the company does report having over $10 million o...